

Bone Therapeutics supports pioneering research by backing projects vital to regenerative medicine research

BONE THERAPEUTICS, the regenerative therapy company addressing unmet medical needs in the field of bone diseases and orthopaedics, is supporting several nationwide pioneering research projects in Belgium that will provide significant value to the field of regenerative medicine.

With its thorough knowledge of regenerative therapy and experience in transition from bench to industry, Bone Therapeutics is a partner of choice to guide fundamental researchers in the development of technologies adaptable to industrial settings. The projects involve leading Belgian universities (ULB, UCL, ULg, UMons, UNamur) as well as several national research centres (Sirris, Cenaero, Materia Nova, Centexbel, ImmuneHealth, CER Groupe and GIGA) that are applying for funding support from the EU and the Walloon Region (incl. DG06).

An initial group of projects, designed to optimize specific cell therapy processes, will:

- Develop innovative biomaterials to improve quality and efficiency of large-scale cell production systems, thereby decreasing costs and hurdles associated with current processes;
- Generate new insights into the use of stem cells, their mode-of-action and homing, through the development of sensitive analytical techniques;
- Establish novel approaches to produce next-generation cell therapy products.

A second group of projects focuses on technological innovations such as the development of superior materials facilitating cellular growth and revascularization which will provide a favourable environment for bone regeneration.

A final group is designed to develop technology platforms aimed at improving the evaluation of the safety and efficacy of cell therapy during the preclinical phase such as a platform for anatomical/molecular imaging and cellular radioactive labelling and a Good Laboratory Practice platform for animal studies with innovative animal models and new imaging tools;

The results of the projects and collaborations could significantly benefit life sciences research and activity in the Walloon Region, as well as stimulate the development of Bone Therapeutics' osteoblastic cell therapy products PREOB[®] and ALLOB[®] along with its new product candidates from the pre-clinical and clinical studies to the production process.

About Bone Therapeutics

Bone Therapeutics is a regenerative therapy company specializing in addressing unmet medical needs in the field of orthopaedics via a minimally invasive approach. Utilizing the Company's unique knowledge of the bone/joint physiology and long-standing expertise in cell therapy and cell transplantation, Bone Therapeutics has created a fully integrated business with an advanced product pipeline comprising novel bone cell products, tailored in-house production methods and minimally invasive treatment techniques.

Bone Therapeutics' autologous bone cell product, PREOB[®], is currently in phase III clinical trials for the treatment of osteonecrosis and non-union fractures. Bone Therapeutics is also developing an allogeneic bone cell therapy product, ALLOB[®], which entered the clinic in 2014 for the treatment of delayed-union fractures. All of Bone Therapeutics' cell therapy products are manufactured to the highest GMP standards, comply with all regulations and are protected by a rich IP estate.

The bone disease and reconstruction market is one of the largest healthcare markets in the world, with more than 4 million procedures requiring bone grafts performed annually in Europe and the USA alone. Bone Therapeutics is operating in areas where demand for new products is high and supply is low, resulting in limited competition. Founded in 2006, Bone Therapeutics is privately held and headquartered in Gosselies (south of Brussels), Belgium. Further information is available at: www.bonetherapeutics.com

Bone Therapeutics SA

Tel: +32 (0)2 529 59 90

Enrico Bastianelli, Chief Executive Officer

Wim Goemaere, Chief Financial Officer

info@bonetherapeutics.com

Consilium Strategic Communications

Amber Bielecka, Mary-Jane

Elliott, Jessica Hodgson, Lindsey Neville

Tel: +44 (0) 20 3 709 5700

bonetherapeutics@consiliumcomms.com

Follow us:   

Be connected:

